Login
Amgen Inc. NASDAQ: AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience
| Name | Amgen Inc. |
| Ticker | AMGN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 247.72 |
| 52W Low/High | 182.24 / 260.95 |
| Market cap | 146 B |
| 1Y Total Return |
28.96%
Strong |
| 1Y Volatility |
35.90%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience
Details
| Ticker | AMGN |
| Name | Amgen Inc. |
| ISIN | US0311621009 |
| CUSIP | 031162100 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) |
|
Share as of 9/18/20
| Close Price | 247.72 |
| 52W Low/High | 182.24 / 260.95 |
| Market cap | 146 B |
| 1Y Total Return |
28.96%
Strong |
| 1Y Volatility |
35.90%
Low Risk |
| Beta | 0.65 |
| PE (trailing) |
20.21
Average |
| 12M Dividends | 6.1 |
| Last Dividend Date | 8/14/20 |
| Dividend Yield | 2.46% |
Fin. Strength
| Net Profit Margin | 30.0% |
| Cash from Op. / Cur. Liabilities | 1.03 |
| Diluted Earnings / Share | 12.26 |
| ROE | 68.0% |
| ROIC | 19.2% |
| Price / Revenue | 6.0 |
| Price / Book | 13.8 |
| Price / CF | 13.5 |
| Current Ratio | 2.2 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 3.21 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
24,301
|
23,562
|
23,188
|
23,050
|
22,474
|
20,765
|
|
| Gross Profit |
19,011
|
19,362
|
19,171
|
18,936
|
18,301
|
16,392
|
|
| R&D |
4,229
|
3,911
|
3,549
|
3,710
|
3,984
|
4,110
|
|
| EBITDA |
12,603
|
12,526
|
13,071
|
13,107
|
11,848
|
9,666
|
|
| Operating Income |
9,202
|
9,855
|
10,242
|
10,301
|
9,154
|
7,023
|
|
| Net Income exc. Extra |
7,299
|
7,958
|
2,364
|
8,174
|
7,433
|
5,814
|
|
| per Share | |||||||
| Diluted avg Shares |
592
|
610
|
660
|
738
|
756
|
768
|
|
| EPS exc. Extra |
12.26
|
12.62
|
3.72
|
10.99
|
9.77
|
7.55
|
|
| Dividend |
6.10
|
5.54
|
4.94
|
4.30
|
3.58
|
2.80
|
|
| Div. Yield (an.) |
2.59%
|
3.01%
|
2.68%
|
2.50%
|
2.35%
|
1.59%
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
65,011
|
59,373
|
67,684
|
79,587
|
75,471
|
71,209
|
|
| Cash, Eq & Invt ShortTerm |
11,421
|
21,758
|
29,395
|
39,227
|
35,034
|
29,993
|
|
| Total Current Assets |
22,895
|
30,746
|
37,970
|
48,442
|
42,947
|
37,736
|
|
| Total Non-Current Assets |
42,116
|
28,627
|
29,714
|
31,145
|
32,524
|
33,473
|
|
| Intangibles |
32,626
|
21,502
|
23,167
|
24,327
|
25,867
|
26,711
|
|
| Total Liabilities |
54,352
|
48,579
|
52,775
|
47,865
|
45,338
|
43,725
|
|
| Total Current Liabilities |
10,523
|
10,622
|
11,205
|
7,815
|
10,830
|
6,891
|
|
| Long Term Debt |
43,829
|
37,957
|
41,570
|
40,050
|
34,508
|
36,834
|
|
| Shareholder equity |
10,659
|
10,794
|
14,909
|
31,722
|
30,133
|
27,484
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
10,867
|
9,726
|
11,295
|
10,473
|
9,557
|
9,329
|
|
| Depreciation |
3,037
|
1,987
|
1,868
|
2,104
|
2,108
|
2,111
|
|
| Cash from Investing |
-2,980
|
2,795
|
15,790
|
-5,581
|
-7,283
|
-5,840
|
|
| Capex |
658
|
656
|
653
|
747
|
639
|
398
|
|
| Cash from Financing |
-4,267
|
-17,127
|
-19,583
|
-4,893
|
-3,439
|
-4,046
|
|
| Stock Issued |
-3,771
|
-9,300
|
-15,539
|
-3,309
|
-2,145
|
-939
|
|
| Debt (LT) Issued |
3,138
|
-4,271
|
-468
|
1,724
|
1,659
|
-936
|
|
| Free Cash Flow |
8,413
|
9,521
|
7,078
|
6,494
|
12,703
|
7,397
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
30.0%
|
33.8%
|
10.2%
|
35.5%
|
33.1%
|
28.0%
|
|
| NCFO / Op.Income |
118.1%
|
98.7%
|
110.3%
|
101.7%
|
104.4%
|
132.8%
|
|
| Current Ratio |
2.2
|
2.9
|
3.4
|
6.2
|
4.0
|
5.5
|
|
| Financial Leverage D/E |
3.21
|
2.84
|
2.31
|
1.11
|
1.10
|
1.16
|
|
| Return on Capital Avg |
19.2%
|
20.7%
|
4.4%
|
13.8%
|
13.1%
|
11.2%
|
|
| Return on Shareholder Equity |
68.0%
|
61.9%
|
10.1%
|
26.4%
|
25.8%
|
22.4%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available